CN107949374B - 稳定的胰高血糖素溶液 - Google Patents

稳定的胰高血糖素溶液 Download PDF

Info

Publication number
CN107949374B
CN107949374B CN201680051139.6A CN201680051139A CN107949374B CN 107949374 B CN107949374 B CN 107949374B CN 201680051139 A CN201680051139 A CN 201680051139A CN 107949374 B CN107949374 B CN 107949374B
Authority
CN
China
Prior art keywords
composition
glucagon
concentration
acid
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201680051139.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN107949374A (zh
Inventor
陈海靓
陈献
诺曼·基思·奥丽达
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LATITUDE PHARMA
Original Assignee
LATITUDE PHARMA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LATITUDE PHARMA filed Critical LATITUDE PHARMA
Publication of CN107949374A publication Critical patent/CN107949374A/zh
Application granted granted Critical
Publication of CN107949374B publication Critical patent/CN107949374B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201680051139.6A 2015-09-04 2016-09-02 稳定的胰高血糖素溶液 Expired - Fee Related CN107949374B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562214831P 2015-09-04 2015-09-04
US62/214,831 2015-09-04
PCT/US2016/050110 WO2017040928A1 (en) 2015-09-04 2016-09-02 Stabilized glucagon solutions

Publications (2)

Publication Number Publication Date
CN107949374A CN107949374A (zh) 2018-04-20
CN107949374B true CN107949374B (zh) 2022-04-08

Family

ID=58188530

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680051139.6A Expired - Fee Related CN107949374B (zh) 2015-09-04 2016-09-02 稳定的胰高血糖素溶液

Country Status (6)

Country Link
US (1) US10888616B2 (enExample)
EP (1) EP3344231B1 (enExample)
JP (1) JP7001584B2 (enExample)
CN (1) CN107949374B (enExample)
CA (1) CA2995392C (enExample)
WO (1) WO2017040928A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107949374B (zh) 2015-09-04 2022-04-08 莱迪杜德制药公司 稳定的胰高血糖素溶液
US11286433B2 (en) * 2017-08-01 2022-03-29 Gaps Technology, Llc Compositions and methods for remediating hydrogen sulfide in hydrocarbon based liquids
CN108174843B (zh) * 2018-01-24 2018-11-13 广州市进德生物科技有限公司 一种胰高血糖素保护剂及其应用
AU2019223659B2 (en) 2018-02-23 2024-09-05 F. Hoffmann-La Roche Ag Dosing unit refilling scheduling
TWI771669B (zh) * 2019-04-26 2022-07-21 美商美國禮來大藥廠 製備穩定胜肽調配物之方法
WO2021168572A1 (en) * 2020-02-25 2021-09-02 Kane Biotech Inc. Stable liquid dispersinb compositions
TW202239427A (zh) * 2020-12-22 2022-10-16 美商美國禮來大藥廠 治療肽調配物
US12128089B2 (en) * 2022-05-26 2024-10-29 Slayback Pharma Llc Stable liquid compositions of glucagon

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1732012A (zh) * 2002-12-27 2006-02-08 迪奥贝克斯公司 用于预防和控制胰岛素诱发的低血糖的组合物和方法
CA2816114A1 (en) * 2010-11-03 2012-05-10 Jan Jezek Novel composition comprising glucagon
CN103442695A (zh) * 2011-03-10 2013-12-11 Xeris药物公司 肠胃外注射用肽药物的稳定制剂
CN103889442A (zh) * 2011-08-10 2014-06-25 阿道恰公司 至少一种基础胰岛素的可注射溶液
CN104159570A (zh) * 2011-12-29 2014-11-19 陈献 稳定的胰高血糖素纳米乳液

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008505087A (ja) * 2004-06-29 2008-02-21 ディオベックス， インコーポレイテッド インスリン誘発性低血糖の予防および制御のための組成物ならびに方法
GB0716385D0 (en) * 2007-08-22 2007-10-03 Camurus Ab Formulations
WO2011011675A1 (en) * 2009-07-23 2011-01-27 Zelos Therapeutics, Inc. Pharmaceutically acceptable formulations/compositions for peptidyl drugs
US9610329B2 (en) * 2009-10-22 2017-04-04 Albireo Pharma, Inc. Stabilized glucagon solutions
US20120046225A1 (en) * 2010-07-19 2012-02-23 The Regents Of The University Of Colorado, A Body Corporate Stable glucagon formulations for the treatment of hypoglycemia
US9334316B2 (en) * 2014-04-11 2016-05-10 Oregon Health & Science University Formulations comprising glucagon
CN107106659B (zh) * 2014-10-27 2022-07-08 莱迪杜德制药公司 肠胃外胰高血糖素制剂
CN107949374B (zh) 2015-09-04 2022-04-08 莱迪杜德制药公司 稳定的胰高血糖素溶液

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1732012A (zh) * 2002-12-27 2006-02-08 迪奥贝克斯公司 用于预防和控制胰岛素诱发的低血糖的组合物和方法
CA2816114A1 (en) * 2010-11-03 2012-05-10 Jan Jezek Novel composition comprising glucagon
CN103442695A (zh) * 2011-03-10 2013-12-11 Xeris药物公司 肠胃外注射用肽药物的稳定制剂
CN103889442A (zh) * 2011-08-10 2014-06-25 阿道恰公司 至少一种基础胰岛素的可注射溶液
CN104159570A (zh) * 2011-12-29 2014-11-19 陈献 稳定的胰高血糖素纳米乳液

Also Published As

Publication number Publication date
JP2018527358A (ja) 2018-09-20
US10888616B2 (en) 2021-01-12
EP3344231B1 (en) 2022-04-13
US20180236079A1 (en) 2018-08-23
EP3344231A4 (en) 2019-03-27
CN107949374A (zh) 2018-04-20
CA2995392A1 (en) 2017-03-09
WO2017040928A1 (en) 2017-03-09
EP3344231A1 (en) 2018-07-11
JP7001584B2 (ja) 2022-01-19
CA2995392C (en) 2023-08-15

Similar Documents

Publication Publication Date Title
CN107949374B (zh) 稳定的胰高血糖素溶液
JP5894174B2 (ja) グルカゴンを含む新規組成物
JP6835831B2 (ja) 非プロトン性極性溶媒中の安定な治療用グルカゴン製剤を製造するための方法
US20140378381A1 (en) Stabilized glucagon nanoemulsions
WO2016196976A1 (en) Glucagon delivery apparatuses and related methods
US20240238381A1 (en) Stable sustained release therapeutic compositions in aprotic polar solvents and methods of manufacturing the same
JP2022534291A (ja) 非プロトン性極性溶媒中の安定な治療用組成物およびその製造方法
US10238717B2 (en) Parenteral glucagon formulations
JP7444786B2 (ja) 低用量の安定なグルカゴンを使用する肥満治療手術後の低血糖症の処置
AU2018388417C1 (en) Treatment of exercise-induced hypoglycemia in type 1 and insulin using type 2 diabetes
AU2018301715B2 (en) Methods for treating congenital hyperinsulinism
WO2024123214A1 (ru) Композиция инсулина аспарта (варианты)
HK40081665A (en) Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
HK40025146A (en) Methods for treating congenital hyperinsulinism

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20220408

CF01 Termination of patent right due to non-payment of annual fee